title: Functional polymorphisms in FAS/FASL system contribute to the risk of occurrence but not progression of gastric cardiac adenocarcinoma.
abstract: OBJECTIVE
  Loss of FAS and gain of aberrant FASL expression are common features of malignant transformation. This study was designed to investigate whether the functional polymorphisms of FAS-1377 G/A (rs2234767) and FASL-844 T/C (rs763110) have an effect on the occurrence and progression of gastric cardiac adenocarcinoma (GCA).
  
  
  METHODS
  Associations of the FAS and FASL polymorphisms with GCA were estimated by OR and their 95% confidence intervals using logistic regression.
  
  
  RESULTS
  In this study, as compared with the wild type homozygote and heterozygote, either the FAS-1377 AA or FASL-844 CC genotype was associated with increased risk of GCA (OR=1.78; 95% CI, 1.19-2.64 and OR=1.92; 95% CI, 1.46-2.54, respectively). Furthermore, individuals with both the FAS-1377 AA and FASL-844 CC genotypes have a higher risk of GCA (OR=4.09; 95% CI, 2.27-7.37) compared to those with the FAS-1377 GG and FASL-844 TT genotypes. Moreover, the FAS-1377 AA genotype increased the risk of GCA among smokers (OR=1.88; 95% CI, 1.11-3.20) but not among non-smokers, suggesting a potential gene-smoking interaction.
  
  
  CONCLUSIONS
  This current study suggests that functional polymorphisms in the apoptotic pathway genes FAS and FASL may significantly contribute to the occurrence of GCA.
authors.affiliation: Zhejiang University School of Medicine, Hangzhou, China.
authors.forename: Weimin
authors.initials: W
authors.lastname: Zhang
authors.forename: Chen
authors.initials: C
authors.lastname: Li
authors.forename: Jing
authors.initials: J
authors.lastname: Wang
authors.forename: Chao
authors.initials: C
authors.lastname: He
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D000328:Adult; D000368:Aged; D002299:Cardia / Q000378:metabolism* / Q000473:pathology; D016022:Case-Control Studies; D002681:China; D018450:Disease Progression; D053222:Fas Ligand Protein / Q000235:genetics* / Q000378:metabolism; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006579:Heterozygote; D006720:Homozygote; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D011401:Promoter Regions, Genetic; D018570:Risk Assessment; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D013274:Stomach Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019014:fas Receptor / Q000235:genetics* / Q000378:metabolism
chemical_list: C491901:FAS protein, human; C505661:FASLG protein, human; D053222:Fas Ligand Protein; D019014:fas Receptor